Precision Medicine

The explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.

We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:

  • Will testing change patient management for this indication?
  • If so, what tests and/or therapies should I use?
  • Should we cover testing and/or therapies?
  • Can we manage these services internally?

Lutetium Lu 177 Dotatate (Lutathera, Advanced Accelerator Applications USA Inc) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Health Problem: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and heterogeneous group of neoplasms derived from neuroendocrine cells within the gastrointestinal tract and pancreas, where curative surgery options are limited. GEP-NETs are estimated to affect approximately 3 individuals per 100,000 people per year.

read more

CANCERPLEX (KEW Inc.)

This report evaluates the analytical validity, clinical validity, and clinical utility of the CANCERPLEX test. According to the laboratory, the test is intended to identify patients who are most likely to respond to immune checkpoint inhibition and detect the presence of human papilloma virus (HPV)/Epstein-Barr virus (EBV) viral integration, which may impact treatment decisio…

read more

4Kscore Test (OPKO Health Inc.)

This report focuses on the analytical validity, clinical validity, and clinical utility of the 4Kscore Test to aid in prostate cancer biopsy decision making for physician and patient through: (1) estimating a patient’s percentage of risk for aggressive (Gleason ≥ 7) prostate cancer if a prostate biopsy were performed; and (2) providing information on the 10-year likelihood of…

read more